suPARnostic® is the only CE-IVD certified product range applied for clinical determination of suPAR (soluble urokinase Plasminogen Activator Receptor) in human plasma and serum.


suPARnostic® is a prognostic biomarker useful for risk stratification of acute medical patients across diseases.

Important clinical benefits include:

  • Advance identification of high-risk patients with unaffected vital signs
  • Identification of patients who can be discharged after treatment
  • Helps to prioritize patients and reduce Emergency Department crowding

suPARnostic® also improves the efficiency of the Emergency Department by shortening the average
patient-length-of-stay
which lead to cost savings.

The suPARnostic® brand consists of the following 3 products:

 

TurbiLatex

For Automated Systems

See product

Quick Triage Test

A Point of Care Solution

See product

ELISA Assay

For Clinical and Research Use

See product